Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial

European Journal of Cancer

Volumn 76, Issue , 2017, Pages 205-215

  Twelves, Chris ^a   Cortés, Javier ^b,g   O'Shaughnessy, Joyce ^c   Awada, Ahmad ^d   Perez, Edith A ^e   Im, Seock–Ah ^f   Gómez Pardo, Patricia ^g   Schwartzberg, Lee S ^h   Diéras, Véronique ⁱ   Yardley, Denise A ^j   Potter, David A ^k   Mailliez, Audrey ^l   Moreno Aspitia, Alvaro ^b   Ahn, Jin Seok ^m   Zhao, Carol ⁿ   Hoch, Ute ⁿ   Tagliaferri, Mary ⁿ   Hannah, Alison L ^o   Rugo, Hope S ^p  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c TEXAS ONCOLOGY   (United States)

^d JULES BORDET INSTITUTE   (Belgium)

^e MAYO CLINIC   (United States)

^f Seoul National University Hospital   (South Korea)

^g VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^h West Clinic   (United States)

ⁱ INSTITUT CURIE   (France)

^j SARAH CANNON RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^l CENTRE OSCAR LAMBRET   (France)

^m Sungkyunkwan University School of Medicine   (South Korea)

ⁿ NEKTAR THERAPEUTICS   (United States)

^o Consultant ^*  (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Advanced breast cancer; Etirinotecan pegol; Metastatic breast cancer; NKTR 102; Quality of life

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DOCETAXEL; ERIBULIN; ETIRINOTECAN PEGOL; GEMCITABINE; IXABEPILONE; PACLITAXEL; TAXANE DERIVATIVE; VINORELBINE TARTRATE; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; EPOTHILONE DERIVATIVE; FURAN DERIVATIVE; FUSED HETEROCYCLIC RINGS; KETONE; MACROGOL DERIVATIVE; TAXOID; VINBLASTINE;

ADULT; ARTICLE; BRAIN METASTASIS; BREAST CANCER SPECIFIC QUALITY OF LIFE QUESTIONNAIRE; CANCER GROWTH; CANCER RECURRENCE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FINANCIAL DEFICIT; GASTROINTESTINAL SYMPTOM; HEALTH STATUS; HUMAN; INSOMNIA; LOSS OF APPETITE; MAJOR CLINICAL STUDY; METASTATIC BREAST CANCER; MIDDLE AGED; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; QUALITY OF LIFE QUESTIONNAIRE CORE 30; RANDOMIZED CONTROLLED TRIAL; AGED; ANALOGS AND DERIVATIVES; ANOREXIA; BODY IMAGE; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CANCER PAIN; CLINICAL TRIAL; COMPARATIVE STUDY; DAILY LIFE ACTIVITY; FEMALE; LIVER NEOPLASMS; LUNG NEOPLASMS; NAUSEA; PATHOLOGY; REPRODUCTIVE HEALTH; SECONDARY; VERY ELDERLY; VOMITING;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ANOREXIA; ANTINEOPLASTIC AGENTS; BODY IMAGE; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CANCER PAIN; DEOXYCYTIDINE; DYSPNEA; EPOTHILONES; FATIGUE; FEMALE; FURANS; HEALTH STATUS; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; KETONES; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NAUSEA; PACLITAXEL; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; REPRODUCTIVE HEALTH; SLEEP INITIATION AND MAINTENANCE DISORDERS; TAXOIDS; VINBLASTINE; VOMITING;

EID: 85016140559     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.02.011     Document Type: Article

References (27)

1. [1] Palumbo, R., Sottotetti, F., Riccardi, A., Teragni, C., Pozzi, E., Quaquarini, E., et al. Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians. Ther Adv Med Oncol 5:6 (2013), 334–350.
2. [2] Marquette, C., Nabelle, L., Chemotherapy-resistant metastatic breast cancer. Curr Treat Options Oncol 13:2 (2012), 263–275.
3. [3] Kiely, B.E., Soon, Y.Y., Tattersall, M.H., Stockler, M.R., How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 29:4 (2011), 456–463.
4. [4] World Health Organization. WHO Cancer factsheet N° 297. Updated February 2015. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/index.html. [Accessed 4 February 2015].
5. [5] Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. 2013, International Agency for Research on Cancer, Lyon, France Available from: http://globocan.iarc.fr [Accessed 17 September 2015].
6. [6] Lin, N.U., Breast cancer brain metastases: new directions in systemic therapy. Ecancermedicalscience, 7, 2013, 307, 10.3332/ecancer.2013.307.
7. [7] André, F., Zielinski, C.C., Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncol 23:Suppl. 6 (2012), vi46–51.
8. [8] Hambrecht, A., Jandial, R., Neman, J., Emerging role of brain metastases in the prognosis of breast cancer patients. Breast Cancer (Dove Med Press) 3 (2011), 79–91.
9. [9] Morris, P.G., McArthur, H.L., Hudis, C.A., Therapeutic options for metastatic breast cancer. Expert Opin Pharmacother 10:6 (2009), 967–981.
10. [10] Bernard-Marty, C., Cardoso, F., Piccart, M.J., Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 9:6 (2004), 617–632.
11. [11] Osoba, D., Health-related quality of life and cancer clinical trials. Ther Adv Med Oncol 3:2 (2012), 57–71.
12. [12] Ganz, P.A., Goodwin, P.J., Health-related quality of life measurement in symptom management trials. J Natl Cancer Inst Monogr 37 (2007), 47–52.
13. [13] Smith, T.J., Temin, S., Alesi, E.R., Abernethy, A.P., Balboni, T.A., Basch, E.M., et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol 30:8 (2012), 880–887.
14. [14] Lemieux, J., Goodwin, P., Bordeleau, L.J., Lauzier, S., Théberge, V., Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001–2009). J Natl Cancer Inst 103 (2011), 1–54.
15. [15] Doward, L.C., Gnanasakthy, A., Baker, M.G., Patient reported outcomes: looking beyond the label. Health Qual Life Outcomes, 8, 2010, 89.
16. [16] Perez, E.A., Awada, A., O'Shaughnessy, J., Rugo, H.S., Twelves, C., Im, S.A., et al. Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracyline- taxane- and capecitabine (BEACON): a randomized, open-label, multicenter, phase 3 trial. Lancet Oncol 16:15 (2015), 1556–1568.
17. [17] Hoch, U., Staschen, C.-M., Johnson, R., Eldon, M.A., Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol 74:6 (2014), 1125–1137.
18. [18] Jameson, G.S., Hamm, J.T., Weiss, G.J., Alemany, C., Anthony, S., Basche, M., et al. Multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res 19:1 (2013), 268–278.
19. [19] Von Hoff, D.D., Jameson, G.S., Borad, M.J., Rosen, L.S., Utz, J., Basche, M., et al. First phase 1 trial of NKTR-102 (peg-irinotecan) reveals early evidence of broad antitumor activity in three different schedules. Eur J Cancer, 6, 2008 (suppl): abstr 595.
20. [20] Rothenberg, M.L., Kuhn, J.G., Rodriguez, F.I., Eckhardt, S.G., Villalona-Calero, M.A., Rinaldi, D.A., et al. Phase 1 dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol 12 (2001), 1631–1641.
21. [21] Aaronson, N.K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N.J., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993), 365–376.
22. [22] Sprangers, M.A., Groenvold, M., Arraras, J.I., Franklin, J., te Velde, A., Muller, M., et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 14 (1996), 2756–2768.
23. [23] Fayers, P.M., Aaronson, N.K., Bjordal, K., Groenvold, M., Curran, D., Bottomley A on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 scoring manual. 3rd ed., 2001, European Organisation for Research and Treatment of Cancer, Brussels.
24. [24] Mallinckrodt, C.H., Sanger, T.M., Dubé, S., DeBrota, D.J., Molenberghs, G., Carroll, R.J., et al. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry 53 (2003), 754–760.
25. [25] Mallinckrodt, C.H., Clark, W.S., David, S.R., Accounting for dropout bias using mixed-effects models. J Biopharm Stat 11 (2001), 9–21.
26. [26] Zeger, S.L., Liang, K.Y., Albert, P.S., Models for longitudinal data: a generalized estimating equation approach. Biometrics 44 (1988), 1049–1060.
27. [27] Awada, A., Garcia, A.A., Chan, S., Jerusalem, G.H., Coleman, R.E., Huizing, M.T., et al. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol 14 (2013), 1216–1225.